New understanding into ways to use cell metabolism to treat cancer may lead to better treatments and outcomes for patients, reports a new study. The findings of the study are published in the journal Cell Reports. A team of //researchers at the University of Cincinnati (UC) College of Medicine have discovered that cell metabolism plays an important role in the ability of cells to start a survival program called autophagy, an unwanted side effect of some anti-cancer drugs that help some tumor cells dodge treatment and eventually regrow into new tumors.
‘New insights into ways to use cell metabolism to 'pull the plug' on tumor cells that survive treatment, can possibly lead to better treatments and outcomes for patients.’
Tweet it Now
These findings provide new insights for ways to use cell metabolism to "pull the plug" on tumor cells that survive treatment, possibly leading to better treatments and outcomes for patients."Cells adapt to nutrient starvation by increasing autophagy, where a cell basically eats itself and recycles cellular contents to support essential processes until nutrients become plentiful once again. This process is regulated by the mammalian target of rapamycin (mTOR) and AMP-activated protein kinases (AMPK)," says Carol Mercer, Ph.D., research assistant professor in the Division of Hematology Oncology, Department of Internal Medicine, and a member of both the Cincinnati Cancer Center and UC Cancer Institute.
"Drugs that target mTOR or activate AMPK are being used in the clinic for some cancers, and are under active investigation for others, making it important to understand how they affect this tumor cell survival pathway."
"We found that cell metabolism significantly influences the ability to begin autophagy, with mitochondrial complex I function being an important factor in the initiation, amplification, and duration of the response," she continues.
"We show that the anti-diabetic drug phenformin, the anti-diabetic drug metformin, and genetic defects in complex I shift cell metabolism toward glycolysis and inhibit the ability of mTOR inhibitors to prompt autophagy. The opposite is also true, as a shift away from glycolysis and toward mitochondrial metabolism, enhances autophagy through a mechanism that involves increased phospholipid metabolism.
Advertisement
Mercer, principal investigator on the study, and her lab worked primarily in cultured cells to understand how metabolism regulates autophagy, identifying strategies to manipulate this pathway to the patients' advantage. This work was built on pre-clinical studies in animal models by Hala Elnakat Thomas, Ph.D., first author and research instructor in the department, who found that the combination of mTOR inhibitors were effective in the treatment of hepatocellular carcinoma (liver cancer) but had the potential disadvantage of increasing autophagy.
Advertisement
Source-Eurekalert